Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of lispro Mix 50/50 versus aspart Mix 30/70 on glycemic variability in diabetes
ChiCTR-IPR-15007340Phase 4Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of insulin lispro + insulin lispro protamine and biphasic insulin aspart in diabetes mellitus (DM) (2 arms), sponsored by Nanjing First Hospital. Primary endpoints: fasting blood glucose, 2-hour postprandial blood glucose and 1 more. Planned start Nov 2015; status: not yet recruiting.
02
Drugs
insulin lispro + insulin lispro protaminebiphasic insulin aspart
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on ChiCTR-IPR-15007340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15007340.